Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.

doi:10.1158/1078-0432.CCR-08-0864

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2008

Ricart Alejandro D, Berlin Jordan D, Papadopoulos Kyriakos P, Syed Samira, Drolet Daniel W, Quaratino-Baker Charlotte, Horan Julie, Chick Jon, Vermeulen Wendy, Tolcher Anthony W, Rowinsky Eric K, Rothenberg Mace L

Abstract excerpt

PURPOSE: To evaluate the safety and describe the pharmacokinetic profile of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, in combination with cisplatin (CDDP) in adults with advanced solid tumors. EXPERIMENTAL DESIGN: CDDP was administered as a 2-h intravenous infusion followed by OSI-7904L intravenously over 30 min, both given every 3 weeks. Doses of each drug were escalated in separate cohorts of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Glutarates

Share to Homocysteine

Share to Maximum Tolerated Dose

Share to Neoplasms

Share to Quinazolines

Share to Thymidylate Synthase

Source

Open in PubMed

Identifiers

PMID: 19047127
DOI: 10.1158/1078-0432.CCR-08-0864

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.PMID 19047127Read ↗

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.Semantic proximity Read ↗

A First-in-human Phase I Study of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Patients With Advanced Solid Tumors With HER2 or HER3 Aberrations.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.Semantic proximity Read ↗

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.Semantic proximity Read ↗

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.Semantic proximity Read ↗

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.Semantic proximity Read ↗

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Semantic proximity Read ↗

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinSemantic proximity Read ↗

Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.Semantic proximity Read ↗

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.